Tritium-labelled isovaleryl-RYYRIK-NH2 as potential antagonist probe for ORL1 nociceptin receptor.
Shogo Inamine, Hirokazu Nishimura, Jinglan Li, Kaname Isozaki, Ayami Matsushima, Tommaso Costa, Yasuyuki Shimohigashi
文献索引:Bioorg. Med. Chem. 22(21) , 5902-9, (2014)
全文:HTML全文
摘要
IsoVa-RYYRIK-NH2 is a highly specific antagonist ligand of the opioid receptor-like 1 (ORL1) receptor, an endogenous ligand of which is 17-mer peptide nociceptin. ORL1 antagonists have potential for clinical use as analgesic and antineuropathic drugs, and thus information on the receptor-binding characteristics of antagonists is very important for rational drug design. In the present study, we prepared tritium-labelled isova-RYYRIK-NH2 from its precursor with the 3-methylcrotonyl (CH3)2CCHCO group by a catalytic reduction using tritium gas. The resulting [(3)H]isoVa-RYYRIK-NH2 was evaluated in a saturation binding assay using the COS-7 cell membrane preparations of transiently expressed ORL1. It exhibited more than 90% specific binding with a dissociation constant of 1.21±0.03nM. From the mutual heterologous binding assays using [(3)H]isoVa-RYYRIK-NH2 and [(3)H]nociceptin, isoVa-RYYRIK-NH2 and nociceptin were found to share the receptor-binding site, but each also had a separate specific binding site of its own. They differentiated the two different binding states or conformations of ORL1, which might represent the agonist-active and antagonist-inactive conformations of ORL1. [(3)H]isoVa-RYYRIK-NH2 is thus a key tracer to uncover the amino acid residues important for receptor inactivation. Copyright © 2014 Elsevier Ltd. All rights reserved.
相关化合物
相关文献:
2012-12-01
[FASEB J. 26 , 4951-65, (2012)]
2011-05-01
[Bioorg. Med. Chem. Lett. 21 , 2736-9, (2011)]
1978-12-01
[Clin. Chim. Acta 90(2) , 187-93, (1978)]
1980-09-08
[Clin. Chim. Acta 106(1) , 85-9, (1980)]
1976-02-01
[J. Pediatr. 88(2) , 229-35, (1976)]